Blood CancerArchives
Response-adapted lenalidomide-dexamethasone (LenDex) intensification after CyBorD induction for transplant-eligible multiple myeloma: the PIANO study
Blood Cancer 1 min.
Blood Cancer
1 min.
Published on 28/07/2026 |
Original article (Full-text)
| Minakata, Daisuke et al. | Blood research. Volume 61(1).
Combination therapy with novel agents is the standard initial treatment for transplant-eligible patients with newly diagnosed multiple myeloma. However, the benefit of additional induction therapy for insufficient response remains unclear. This multicenter prospective study investigated response-adapted...
Asciminib as first-line therapy in chronic myeloid leukemia: a systematic review
Blood Cancer 1 min.
Blood Cancer
1 min.
Published on 21/07/2026 |
Original article (Full-text)
| Han, Jae Joon et al. | Blood research. Volume 61(1).
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the BCR::ABL1 fusion oncogene. Asciminib, a first-in-class STAMP (Specifically Targeting the ABL Myristoyl Pocket) inhibitor, represents a novel therapeutic approach distinct from conventional ATP-competitive tyrosine kinase...
